ポイントオブケアバイオセンサー市場- 世界の産業規模、シェア、動向、機会、予測、製品別、プラットフォーム別、エンドユーザー別、地域別、競合別、2019年～2029年

ポイントオブケアバイオセンサーの世界市場規模は2023年に730億1,000万米ドルとなり、予測期間のCAGRは2029年まで7.89%で堅調な成長が予測されています。

ポイントオブケアバイオセンサーの世界市場は、幅広いヘルスケア産業の中でも、急速な成長と技術進歩が著しいダイナミックなセグメントです。ポイント・オブ・ケア型バイオセンサーは、患者のいる場所やその近くでリアルタイムの診断情報を提供するように設計された革新的なデバイスであり、集中的な検査室での検査を不要にすることで、医療従事者の意思決定を合理化します。この市場には、電気化学センサー、光学センサー、圧電センサーなど、さまざまなバイオセンサー技術が含まれ、それぞれが感度、特異性、携帯性において明確な利点を提供しています。糖尿病、心血管疾患、感染症などの慢性疾患の有病率が増加しており、タイムリーで正確な診断ソリューションが必要とされていることなどが、世界市場の拡大を後押ししています。さらに、個別化医療に対する需要の高まりと在宅ヘルスケアソリューションの採用が、ポイント・オブ・ケア型バイオセンサーの需要拡大に寄与しています。ナノテクノロジー、マイクロ流体工学、ワイヤレス接続の進歩も、これらの機器の性能と使いやすさを向上させ、市場の成長をさらに促進しています。

北米と欧州は、確立されたヘルスケアインフラ、高い医療費、政府の支援策などの恩恵を受け、世界市場をリードしています。しかし、アジア太平洋地域では、ヘルスケア支出の増加、ヘルスケアインフラの改善、ポイントオブケア診断の利点に関する認知度の向上により、今後数年間で大きな成長が見込まれています。有望な成長見通しとは裏腹に、市場は規制上のハードル、償還の問題、既存のヘルスケアシステムへのバイオセンサーの統合の複雑さといった課題に直面しています。しかし、業界関係者、研究機関、ヘルスケアプロバイダー間の協力と研究開発への投資により、イノベーションが促進され、これらの課題を克服することが期待されます。Point-of-careバイオセンサーの世界市場は、患者の予後を向上させ、世界中のヘルスケア提供を変革する、コスト効率が高く、ユーザーフレンドリーで信頼性の高いバイオセンサー・ソリューションの開発を目指す企業に有利な機会を提供します。

主な市場促進要因

慢性疾患の有病率の上昇

疾病の早期発見の重要性の高まり

バイオセンサー技術の進歩

主な市場課題

規制上のハードル

償還の問題

既存のヘルスケア・システムとの統合

主な市場動向

個別化医療へのシフト

在宅ヘルスケアへの需要の高まり

セグメント別インサイト

製品別インサイト

地域別インサイト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 ポイントオブケアバイオセンサーの世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（グルコースモニタリング、HIV、C型肝炎、妊娠）
  • プラットフォーム別（マイクロ流体、ディップスティック、イムノアッセイ）
  • エンドユーザー別（病院・クリニック、薬局、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 製品別
  • プラットフォーム別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋地域のポイントオブケアバイオセンサー市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • プラットフォーム別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のポイントオブケアバイオセンサー市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • プラットフォーム別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のポイントオブケアバイオセンサー市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • プラットフォーム別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のポイントオブケアバイオセンサー市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • プラットフォーム別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのポイントオブケアバイオセンサー市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • プラットフォーム別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品発表（ある場合）
• M&A（もしあれば）

第13章 ポイントオブケアバイオセンサーの世界市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Abbott Laboratories Inc.
• Koninklijke Philips N.V.
• GE HealthCare Technologies Inc
• Accubiotech Co, Ltd.
• ACON Laboratories, Inc
• Becton, Dickinson and Company
• Biolytical Laboratories Inc.
• Danaher Corporation（HemoCue）
• Siemens Healthineers AG
• Meridian Bioscience, Inc

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Point-of-care Biosensors Market was valued at USD 73.01 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.89% through 2029. The Global Point-of-care Biosensors Market is a dynamic segment within the broader healthcare industry, marked by rapid growth and technological advancements. Point-of-care biosensors are innovative devices designed to deliver real-time diagnostic information at or near the patient's location, streamlining decision-making for healthcare professionals by eliminating the need for centralized laboratory testing. This market encompasses various biosensor technologies, such as electrochemical, optical, and piezoelectric sensors, each offering distinct advantages in sensitivity, specificity, and portability. Driving the expansion of the global market are factors like the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases, which necessitate timely and precise diagnostic solutions. Furthermore, the rising demand for personalized medicine and the adoption of home-based healthcare solutions are contributing to the growing demand for point-of-care biosensors. Advancements in nanotechnology, microfluidics, and wireless connectivity are also enhancing the performance and usability of these devices, further propelling market growth.

North America and Europe lead the global market, benefiting from well-established healthcare infrastructure, high healthcare expenditure, and supportive government initiatives. However, significant growth is anticipated in the Asia-Pacific region in the coming years due to rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about the advantages of point-of-care diagnostics. Despite promising growth prospects, the market faces challenges such as regulatory hurdles, reimbursement issues, and the complexity of integrating biosensors into existing healthcare systems. Nonetheless, collaborations between industry players, research institutions, and healthcare providers, coupled with investments in research and development, are expected to drive innovation and surmount these challenges. The Global Point-of-care Biosensors Market offers lucrative opportunities for companies aiming to develop cost-effective, user-friendly, and reliable biosensor solutions that enhance patient outcomes and transform healthcare delivery worldwide.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The escalating incidence of chronic ailments is a key driver propelling the expansion of the Global Point-of-care Biosensors Market. Chronic conditions like diabetes, cardiovascular ailments, and infectious diseases are placing substantial strains on healthcare systems worldwide, fueling the demand for efficient diagnostic solutions. Point-of-care biosensors provide swift and user-friendly testing capabilities, facilitating early detection and treatment management of these enduring health issues.

Diabetes, notably, has attained epidemic proportions globally, with cases continuing to soar. Point-of-care biosensors play a pivotal role in diabetes management by furnishing patients with real-time insights into their blood glucose levels, enabling prompt adjustments to medication, diet, and lifestyle. These devices empower diabetes patients to closely monitor their condition, mitigating the risk of complications and enhancing overall quality of life. Cardiovascular diseases, encompassing heart disease and stroke, stand as leading causes of mortality worldwide. Point-of-care biosensors can identify biomarkers linked to cardiac events, such as troponin levels, facilitating swift diagnosis and intervention during emergencies. By furnishing immediate information at the point of care, these biosensors aid healthcare providers in delivering timely treatment, thereby improving patient outcomes and alleviating the burden on healthcare facilities.

Infectious diseases also significantly contribute to the growing demand for point-of-care biosensors. The ongoing COVID-19 pandemic has underscored the significance of rapid diagnostic testing in curbing the spread of infectious diseases. Point-of-care biosensors capable of detecting viral antigens or antibodies play a critical role in screening, diagnosis, and surveillance efforts, enabling early case identification and prompt implementation of public health measures. The aging population and evolving lifestyles are further driving the surge in chronic disease prevalence globally. As individuals live longer and encounter increased exposure to risk factors such as sedentary lifestyles, unhealthy diets, and environmental pollutants, the incidence of chronic conditions continues to escalate. Point-of-care biosensors offer a convenient and accessible solution for monitoring and managing these chronic diseases, empowering individuals to proactively address their health concerns.

Growing Emphasis on Early Disease Detection

The increasing focus on early disease detection drives the growth of the Global Point-of-care Biosensors Market. Early disease detection is crucial for enhancing patient outcomes, facilitating timely intervention and treatment, resulting in improved prognosis and reduced healthcare expenditures. Point-of-care biosensors play a vital role in early disease detection by offering rapid and precise diagnostic testing outside conventional laboratory environments.

A key advantage of point-of-care biosensors is their capability to deliver instant results at the point of care, enabling healthcare professionals to initiate treatment promptly. This is particularly critical for conditions where early intervention is paramount, such as cancer, infectious diseases, and cardiovascular diseases. Point-of-care biosensors can identify biomarkers associated with these diseases, enabling early diagnosis and facilitating timely referral to specialized care as necessary. Cancer, a leading cause of morbidity and mortality globally, necessitates early detection for enhancing survival rates. Point-of-care biosensors capable of detecting cancer biomarkers in blood, urine, or other bodily fluids offer a promising avenue for early cancer detection. These biosensors facilitate screening and diagnosis in primary care settings, enabling timely detection of tumors before they become symptomatic or progress to advanced stages.

Infectious diseases also benefit from early detection through point-of-care biosensors, particularly in outbreak situations or resource-limited settings. Rapid diagnostic tests for infectious diseases like malaria, HIV, and tuberculosis enable healthcare providers to promptly identify cases and implement appropriate treatment and control measures, mitigating transmission and preventing further disease spread. Point-of-care biosensors serve as valuable tools for early detection and management of chronic diseases like diabetes and cardiovascular diseases. By providing patients with real-time health status information, these devices empower individuals to monitor their condition closely and make informed decisions regarding treatment and lifestyle choices. Early detection of complications such as hyperglycemia or hypertension can help avert serious adverse events and enhance long-term health outcomes.

Technological Advancements in Biosensor Technologies

Technological advancements in biosensor technologies are driving growth in the Global Point-of-care Biosensors Market. These innovations are transforming diagnostics by enhancing the sensitivity, accuracy, user-friendliness, and cost-effectiveness of point-of-care biosensors.

Miniaturization stands out as a key advancement propelling point-of-care biosensors. Compact and portable, miniaturized biosensors require minimal sample volumes, making them ideal for testing in diverse healthcare settings, including clinics, hospitals, and remote areas. This downsizing owes to progress in microfabrication techniques and nanotechnology, enabling the creation of lightweight biosensor devices easily integrated into handheld or wearable platforms. Increased sensitivity is another vital advancement. Heightened sensitivity allows biosensors to detect analytes at very low concentrations, enhancing their accuracy in diagnosing diseases and identifying early-stage biomarkers. Innovations in sensor design, surface chemistry, and signal amplification techniques contribute to significant sensitivity improvements, boosting point-of-care biosensor performance across various applications.

Enhanced connectivity capabilities also contribute to market growth. Modern biosensors feature wireless communication technologies like Bluetooth and Wi-Fi, facilitating seamless data transfer to smartphones, tablets, or cloud-based platforms. This connectivity enables remote patient data monitoring, real-time sharing of test results with healthcare providers, and integration with electronic health records, improving point-of-care diagnostics efficiency and accessibility. Advancements in biosensor technologies have led to multiplexed and multiparametric biosensors capable of simultaneously detecting multiple analytes in a single sample. These biosensors offer benefits such as reduced sample volume requirements, faster testing times, and cost savings. Such capabilities are particularly valuable in applications like infectious disease diagnostics, where simultaneous detection of multiple pathogens or biomarkers is crucial for accurate diagnosis and treatment.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the Global Point-of-care Biosensors Market is navigating complex regulatory landscapes. Obtaining regulatory approvals for new biosensor devices can be a lengthy and expensive process, involving rigorous testing and documentation requirements. Differences in regulatory requirements across regions further complicate matters, requiring manufacturers to navigate multiple regulatory frameworks. Delays in obtaining regulatory approvals can hinder market entry and slow down innovation, stifling growth in the point-of-care biosensors market.

Reimbursement Issues

Another significant challenge for the Global Point-of-care Biosensors Market is the lack of adequate reimbursement policies for point-of-care diagnostic tests. Reimbursement policies vary widely between countries and regions, and many healthcare systems do not provide adequate reimbursement for point-of-care testing. This lack of reimbursement poses a financial barrier for patients and healthcare providers, limiting the adoption of point-of-care biosensors. Without proper reimbursement mechanisms in place, the market viability of these devices may be compromised, hindering their widespread adoption and utilization in clinical practice.

Integration with Existing Healthcare Systems

Integrating point-of-care biosensors into existing healthcare systems presents a significant challenge for manufacturers and healthcare providers alike. Compatibility issues with electronic health record systems, data management protocols, and interoperability standards can impede seamless integration of biosensor data into clinical workflows. Moreover, healthcare professionals may require additional training to use point-of-care biosensors effectively, further complicating integration efforts. Addressing these integration challenges is essential to maximize the utility and impact of point-of-care biosensors in healthcare delivery.

Key Market Trends

Shift towards Personalized Medicine

The shift towards personalized medicine is significantly boosting the Global Point-of-care Biosensors Market, reshaping how healthcare is delivered and diagnostic solutions are utilized. Personalized medicine, also known as precision medicine, involves tailoring medical treatment to individual patient characteristics, such as genetic makeup, lifestyle factors, and disease biomarkers. Point-of-care biosensors are playing a crucial role in facilitating personalized medicine by providing real-time diagnostic information at the patient's location, enabling healthcare providers to make informed treatment decisions based on personalized patient data.

One of the key advantages of point-of-care biosensors in personalized medicine is their ability to deliver rapid and accurate diagnostic results outside traditional laboratory settings. These devices empower healthcare professionals to obtain timely information about a patient's health status, enabling them to customize treatment plans based on individual patient needs. For example, in oncology, point-of-care biosensors can detect cancer biomarkers in blood or tissue samples, allowing for early detection of tumors and targeted therapy selection based on the tumor's molecular profile.

Additionally, point-of-care biosensors enable patients to actively participate in their healthcare decisions by providing them with access to real-time diagnostic data. Patients can monitor their health conditions conveniently and proactively, leading to better self-management of chronic diseases and improved treatment adherence. This level of patient engagement and empowerment is essential for achieving optimal treatment outcomes in personalized medicine.

Furthermore, the adoption of point-of-care biosensors supports the broader goals of personalized medicine by facilitating the implementation of precision diagnostics and targeted therapies. These devices enable healthcare providers to identify specific disease biomarkers and molecular targets, allowing for the development of tailored treatment strategies that maximize therapeutic efficacy and minimize adverse effects. By delivering precise and actionable diagnostic information, point-of-care biosensors contribute to the optimization of patient care in personalized medicine.

Rising Demand for Home-based Healthcare

The rising demand for home-based healthcare is significantly boosting the Global Point-of-care Biosensors Market, transforming the way healthcare is delivered and diagnostic solutions are utilized. Home-based healthcare refers to the provision of medical services and monitoring of health conditions in patients' homes, rather than in traditional clinical settings. Point-of-care biosensors play a pivotal role in enabling home-based healthcare by providing rapid and convenient diagnostic testing capabilities that empower patients to monitor their health conditions conveniently and proactively.

One of the key advantages of point-of-care biosensors in home-based healthcare is their ability to deliver immediate results at the point of care. These devices enable patients to perform diagnostic tests in the comfort of their homes, eliminating the need for frequent visits to healthcare facilities. Patients can monitor their health conditions regularly, track changes in their biomarkers, and take proactive measures to manage chronic diseases effectively. This level of self-management empowers patients to take control of their health and improve their overall well-being.

Point-of-care biosensors enable remote monitoring of patients' health conditions by healthcare providers, allowing for timely intervention and personalized care. Healthcare professionals can remotely access patients' diagnostic data in real-time, enabling them to identify potential health issues early and adjust treatment plans accordingly. This proactive approach to healthcare management can lead to better outcomes, reduced hospitalizations, and improved patient satisfaction.

Furthermore, the adoption of point-of-care biosensors supports the broader goals of home-based healthcare by enhancing accessibility to medical services and reducing healthcare costs. These devices enable patients to perform diagnostic tests at home without the need for specialized equipment or trained personnel, saving time and resources associated with traditional laboratory testing. By decentralizing diagnostic testing and shifting care delivery to patients' homes, point-of-care biosensors contribute to the optimization of healthcare resources and the improvement of healthcare efficiency. The rising demand for home-based healthcare is driven by various factors, including an aging population, increasing prevalence of chronic diseases, and advancements in telemedicine technologies. As healthcare systems worldwide face challenges such as limited healthcare infrastructure and rising healthcare costs, there is a growing emphasis on shifting healthcare delivery from traditional clinical settings to patients' homes. Point-of-care biosensors play a critical role in enabling this transition by providing rapid, convenient, and cost-effective diagnostic testing solutions that support home-based healthcare delivery.

Segmental Insights

Product Insights

Based on the product, the glucose monitoring segment emerged as the dominant segment in the global point-of-care biosensors market in 2023. The increasing prevalence of diabetes globally has propelled the demand for glucose monitoring devices. With diabetes becoming a major public health concern, there is a growing need for convenient and accurate methods of monitoring blood glucose levels to manage the condition effectively. Point-of-care glucose biosensors offer a rapid and convenient way to measure blood glucose levels, empowering individuals with diabetes to monitor their condition closely and make informed decisions about their treatment and lifestyle.

Regional Insights

North America emerged as the dominant player in the global point-of-care biosensors market in 2023, holding the largest market share. North America boasts a robust healthcare infrastructure and a highly developed healthcare ecosystem, which fosters innovation and adoption of advanced medical technologies. The region is home to numerous leading healthcare institutions, research organizations, and medical device companies that drive advancements in point-of-care biosensors. Additionally, strong government support for healthcare innovation, coupled with favorable regulatory policies, accelerates the commercialization and adoption of point-of-care biosensors in North America.

Key Market Players

Abbott Laboratories Inc.

Koninklijke Philips N.V.

Accubiotech Co, Ltd.

ACON Laboratories, Inc

Becton, Dickinson and Company

Biolytical Laboratories Inc.

Danaher Corporation (HemoCue)

Siemens Healthineers AG

Meridian Bioscience, Inc

GE HealthCare Technologies Inc.

Report Scope:

In this report, the Global Point-of-care Biosensors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-of-care Biosensors Market, By Product:

Glucose Monitoring HIV Hepatitis C Pregnancy

Point-of-care Biosensors Market, By Platforms:

Microfluidics Dipsticks Immunoassays

Point-of-care Biosensors Market, By End-User:

Hospitals & Clinics Pharmacy Others

Point-of-care Biosensors Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-of-care Biosensors Market.

Available Customizations:

Global Point-of-care Biosensors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of customer

5. Global Point-of-care Biosensors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Glucose Monitoring, HIV, Hepatitis C, Pregnancy)
  • 5.2.2. By Platforms (Microfluidics, Dipsticks, Immunoassays)
  • 5.2.3. By End User (Hospitals & Clinics, Pharmacy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Platforms
  • 5.3.3. By End User
  • 5.3.4. By Region

6. Asia Pacific Point-of-care Biosensors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Platforms
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Point-of-care Biosensors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Platforms
      • 6.3.1.2.3. By End User
  • 6.3.2. India Point-of-care Biosensors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Platforms
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Point-of-care Biosensors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Platforms
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Point-of-care Biosensors Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Platforms
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Point-of-care Biosensors Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Platforms
      • 6.3.5.2.3. By End User

7. Europe Point-of-care Biosensors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Platforms
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Point-of-care Biosensors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Platforms
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Point-of-care Biosensors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Platforms
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Point-of-care Biosensors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Platforms
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Point-of-care Biosensors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Platforms
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Point-of-care Biosensors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Platforms
      • 7.3.5.2.3. By End User

8. North America Point-of-care Biosensors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Platforms
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Point-of-care Biosensors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Platforms
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Point-of-care Biosensors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Platforms
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Point-of-care Biosensors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Platforms
      • 8.3.3.2.3. By End User

9. South America Point-of-care Biosensors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Platforms
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Point-of-care Biosensors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Platforms
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Point-of-care Biosensors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Platforms
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Point-of-care Biosensors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Platforms
      • 9.3.3.2.3. By End User

10. Middle East and Africa Point-of-care Biosensors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Platforms
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Point-of-care Biosensors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Platforms
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Point-of-care Biosensors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Platforms
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Point-of-care Biosensors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Platforms
      • 10.3.3.2.3. By End User
  • 10.3.4. Egypt Point-of-care Biosensors Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Platforms
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches (If Any)
• 12.3. Mergers & Acquisitions (If Any)

13. Global Point-of-care Biosensors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Koninklijke Philips N.V.
• 15.3. GE HealthCare Technologies Inc
• 15.4. Accubiotech Co, Ltd.
• 15.5. ACON Laboratories, Inc
• 15.6. Becton, Dickinson and Company
• 15.7. Biolytical Laboratories Inc.
• 15.8. Danaher Corporation (HemoCue)
• 15.9. Siemens Healthineers AG
• 15.10. Meridian Bioscience, Inc

16. Strategic Recommendations

17. About Us & Disclaimer